Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, has been awarded a New Investigator Award from the International Society of CNS Clinical Trials and Methodology (ISCTM).
The award was presented at the organization’s conference held Feb. 19-21 in Washington, D.C., where Wilkinson presented research on the impact of midazolam vs. saline on the effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant.
Wilkinson’s research was published ahead of print in the journal Neuropsychopharmacology. Click here to read the abstract.
ISCTM is a multi-disciplinary independent organization “devoted to promoting advances that address strategic clinical, regulatory, methodological and policy challenges that arise in the development and use of CNS therapeutic agents,” according to its website.